Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.574
0.00 (0.00%)
At close: Jun 26, 2026, 4:00 PM EDT
0.545
-0.028 (-4.92%)
After-hours: Jun 26, 2026, 7:20 PM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2025, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,167
Market Cap
3.77M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| FibroBiologics | 15 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Artelo Biosciences | 7 |
| GRI Bio | 4 |
| CDT Equity | 4 |
| SciSparc | 3 |
GLMD News
- 6 days ago - Galmed announces restructured acquisition terms for Colospan - TheFly
- 6 days ago - Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd. - PRNewsWire
- 20 days ago - Galmed to acquire Colospan in cash and stock deal - TheFly
- 20 days ago - Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - PRNewsWire
- 26 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 26 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 26 days ago - Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PRNewsWire
- 6 weeks ago - Galmed reports results from first-in-man PK study of Aramchol Meglumine - TheFly